TNF and metabolic dysfunction-associated steatohepatitis: All drug treatments diminished circulating TNF-α level significantly, in a similar and dose-dependent manner (N30, N15) or more effective manner (N15 + VitE) than UDCA, as compared to the NASH group (P < 0.05).